The mechanism of action of interferon-β in relapsing multiple sclerosis

CNS Drugs

Volumn 25, Issue 6, 2011, Pages 491-502

  Kieseier, Bernd C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Interferon beta; Interferon beta 1a; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; CD56 ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERFERON BETA SERINE; NERVE GROWTH FACTOR; PEGINTERFERON; PEGINTERFERON BETA1A; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

APOPTOSIS; ASTHENIA; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; BRAIN ATROPHY; BRAIN DAMAGE; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEPRESSION; DISABILITY; DISEASE COURSE; DOWN REGULATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; FLU LIKE SYNDROME; HELPER CELL; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; INJECTION SITE REACTION; LEUKOCYTE MIGRATION; MULTIPLE SCLEROSIS; MYALGIA; NATURAL KILLER CELL; NERVE CELL; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SYMPTOM; TH1 CELL; TH17 CELL;

HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 79958108785     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11591110-000000000-00000     Document Type: Review

References (100)

1. Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9. (Pubitemid 27153632)
2. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85. (Pubitemid 28065253)
3. Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-12.
4. Haines JL, Ter-Minassian M, Bazyk A, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex: the Multiple Sclerosis Genetics Group. Nat Genet 1996; 13: 469-71. (Pubitemid 26256623)
5. Olsson T, Hillert J. The genetics of multiple sclerosis and its experimental models. Curr Opin Neurol 2008; 21: 255-60. (Pubitemid 351653973)
6. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Mul- tiple sclerosis. N Engl J Med 2000; 343: 938-52.
7. Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005; 4: 195-202. (Pubitemid 40269150)
8. McCandless EE, Piccio L, Woerner BM, et al. Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am J Pathol 2008; 172: 799-808. (Pubitemid 351354551)
9. McCandless EE, Budde M, Lees JR, et al. IL-1R signaling within the central nervous system regulates CXCL12 expression at the blood-brain barrier and disease severity during experimental autoimmune encephalomyelitis. J Immunol 2009; 183: 613-20.
10. Platten M, Steinman L. Multiple sclerosis: trapped in deadly glue. Nat Med 2005; 11: 252-3. (Pubitemid 40460548)
11. Fletcher JM, Lalor SJ, Sweeney CM, et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010; 162: 1-11.
12. Venken K, Hellings N, Liblau R, et al. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med 2010; 16: 58-68.
13. Pettinelli CB, McFarlin DE. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol 1981; 127: 1420-3. (Pubitemid 11021014)
14. Zamvil S, Nelson P, Trotter J, et al. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 1985; 317: 355-8. (Pubitemid 15232523)
15. Aranami T, Yamamura T. Th17 cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 2008; 57: 115-20. (Pubitemid 351897665)
16. Sun D, Whitaker JN, Huang Z, et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 2001; 166: 7579-87. (Pubitemid 32525639)
17. Huseby ES, Liggitt D, Brabb T, et al. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 2001; 194: 669-76. (Pubitemid 32844776)
18. Sutton CE, Lalor SJ, Sweeney CM, et al. Interleukin-1 and IL-23 induce innate IL-17 production from gamma delta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009; 31: 331-41.
19. Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51: 682-9. (Pubitemid 28449243)
20. Dhib-Jabut. Pathogenesis of myelin/oligodendrocyte da- mage in multiple sclerosis. Neurology 2007; 68 (22 Suppl. 3): S13-21.
21. Arnason BG, Dayal A, Qu ZX, et al. Mechanisms of action of interferon-beta in multiple sclerosis. Springer Sem Im-munopathol 1996; 18: 125-48. (Pubitemid 26159559)
22. Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998; 187: 537-46. (Pubitemid 28093356)
23. Renkl AC, Wussler J, Ahrens T, et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 2005; 106: 946-55. (Pubitemid 41076439)
24. van Boxel-Dezaire AH, Hoff SC, van Oosten BW, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999; 45: 695-703. (Pubitemid 29260746)
25. Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 2010; 1812: 252-64.
26. Waubant E, Goodkin DE, Gee L, etal. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999; 53: 1397-401. (Pubitemid 29491927)
27. Leppert D, Ford J, Stabler G, et al. Matrix metalloprotei- nase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998; 121: 2327-34. (Pubitemid 28552469)
28. Waubant E, Goodkin D, Bostrom A, et al. IFNX lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 2003; 60: 52-7. (Pubitemid 36070643)
29. Boz C, Ozmenoglu M, Velioglu S, et al. Matrix metallo- proteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg 2006; 108: 124-8. (Pubitemid 43075529)
30. Neumann H. Molecular mechanisms of axonal damage in inflammatory central nervous systems diseases. Curr Opin Neurol 2003; 16: 247-52.
31. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295-302. (Pubitemid 29378163)
32. Trapp BD, Ransohoff RM, Fisher E, et al. Neurodegen- eration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999; 5: 48-57. (Pubitemid 29058945)
33. Liuzzi G, Trojano M, Fanelli M, et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 2002; 8: 222-8. (Pubitemid 34654058)
34. Bitsch A, da Costa C, Bunkowski S, et al. Identification of macrophage populations expressing tumor necrosis factor-alpha mRNA in acute multiple sclerosis. Acta Neuro-pathol 1998; 95: 373-7. (Pubitemid 28142546)
35. Takeuchi M, Keino H, Suzuki J, et al. Possibility of indu- cing anterior chamber-associated immune deviation by TGF-beta2 treatment of monocytes isolated from Behçet's patients. Exp Eye Res 2006; 83: 981-8. (Pubitemid 44292693)
36. Muzio L, Martino G, Furlan R. Multifaceted aspects of inflammation in multiple sclerosis: the role of microglia. J Neuroimmunol 2007; 191: 39-44. (Pubitemid 350060997)
37. Villoslada P, Hauser SL, Bartke I, et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 2000; 191: 1799-806. (Pubitemid 30331576)
38. Flugel A, Matsumuro K, Neumann H, et al. Antiin- flammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur J Immunol 2001; 31: 11-22.
39. Kohm AP, Carpentier PA, Anger HA, et al. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 2002; 169: 4712-6. (Pubitemid 35217131)
40. + regulatory T cells. Int Immunol 2004; 16: 249-56. (Pubitemid 38195655)
41. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the life-span of mice. Nat Immunol 2007; 8: 191-7. (Pubitemid 46152650)
42. Anderton SM, Liblau RS. Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system. Curr Opin Neurol 2008; 21: 248-54. (Pubitemid 351653972)
43. Kozovska ME, Hong J, Zang YC, et al. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999; 53: 1692-7. (Pubitemid 29530341)
44. Liu Z, Pelfrey CM, Cotleur A, et al. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 2001; 112: 153-62.
45. Chen M, Chen G, Nie H, et al. Regulatory effects of IFN- betaonproductionofosteopontin and IL-17 byCD4+ T cells in MS. Eur J Immunol 2009; 39: 2525-36.
46. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008; 118: 1680-90. (Pubitemid 351632372)
47. Shinohara ML, Kim JH, Garcia VA, et al. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteo-pontin. Immunity 2008; 29: 68-78.
48. Prinz M, Schmidt H, Mildner A, et al. Distinct and non- redundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008; 28: 675-86.
49. Krakauer M, Sorensen P, Khademi M, et al. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler 2008; 14: 622-30. (Pubitemid 351954404)
50. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relap-sing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7: 796-804.
51. Mirandola SR, Hallal DE, Farias AS, et al. Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis. Int Immunopharmacol 2009; 9: 824-30.
52. Carrieri PB, Ladogana P, Di Spigna G, et al. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders. Immunopharmacol Immunotoxicol 2008; 30: 1-9.
53. Chabot S, Williams G, Yong VW. Microglial production of TNF-alpha is induced by activated T lymphocytes: involvement of VLA-4 and inhibition by interferonbeta-1b. J Clin Invest 1997; 100: 604-12. (Pubitemid 27340508)
54. Muraro PA, Leist T, Bielekova B, et al. VLA-4/CD49d downregulated on primed T lymphocytes during inter-feron-beta therapy in multiple sclerosis. J Neuroimmunol 2000; 111: 186-94.
55. Muraro PA, Liberati L, Bonanni L, et al. Decreased in- tegrin gene expression in patients with MS responding to interferon-beta treatment. J Neuroimmunol 2004; 150: 123-31. (Pubitemid 38481655)
56. Avolio C, Filippi M, Tortorella C, et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 2005; 11: 441-6. (Pubitemid 40984239)
57. Corsini E, Gelati M, Dufour A, et al. Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMCs, HUVECs and MS-HBECs: an in vivo and in vitro study. J Neuroimmunol 1997; 79: 76-83. (Pubitemid 27454686)
58. Gelati M, Corsini E, Dufour A, et al. Immunological ef- fects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up. J Neurol 1999; 246: 569-73. (Pubitemid 29376282)
59. Defazio G, Gelati M, Corsini E, et al. In vitro modulation of adhesion molecules, adhesion phenomena, and fluid phase endocytosis on human umbilical vein endothelial cells and brain-derived microvascular endothelium by IFN-beta 1a. J Interferon Cytokine Res 2001; 21: 267-72. (Pubitemid 32727424)
60. Defazio G, Livrea P, Giorelli M, et al. Interferon beta-1a downregulates TNFalpha-induced intercellular adhesion molecule 1 expression on brain microvascular endothelial cells through a tyrosine kinase-dependent pathway. Brain Res 2000; 881: 227-30.
61. Defazio G, Trojano M, Ribatti D, et al. ICAM 1 expression and fluid phase endocytosis of cultured brain micro-vascular endothelial cells following exposure to interferon beta-1a and TNFalpha. J Neuroimmunol 1998; 88: 13-20. (Pubitemid 28342898)
62. Salama HH, Kolar OJ, Zang YC, et al. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis. Mult Scler 2003; 9: 28-31. (Pubitemid 36253692)
63. Leppert D, Waubant E, Burk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846-52. (Pubitemid 27044602)
64. Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853-63. (Pubitemid 27044603)
65. Jin S, Kawanokuchi J, Mizuno T, et al. Interferon-beta is neuroprotective against the toxicity induced by activated microglia. Brain Res 2007; 1179: 140-6. (Pubitemid 47633507)
66. Biernacki K, Antel JP, Blain M, et al. Interferon beta pro- motes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol 2005; 62: 563-8. (Pubitemid 40489886)
67. Boutros T, Croze E, Yong VW. Interferon-beta is a potent promoter of nerve growth factor production by astro-cytes. J Neurochem 1997; 69: 939-46. (Pubitemid 27364813)
68. Saraste M, Irjala H, Airas L. Expansion of CD56bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 2007; 28: 121-6. (Pubitemid 47039837)
69. Vandenbark AA, Huan J, Agotsch M, et al. Interferon- beta-1a treatment increases CD56(bright) natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 2009; 215 (1-2): 125-8.
70. Sellebjerg F, Datta P, Larsen J, et al. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler 2008; 14: 615-21. (Pubitemid 351954403)
71. Weinstock-Guttman B, Bhasi K, Badgett D, et al. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol 2008; 205: 113-25.
72. Kauffman MA, Yankilevich P, Barrero P, et al. Whole genome analysis of the action of interferon-beta. Int J Clin Pharmacol Ther 2009; 47: 328-57.
73. Balashov KE, Aung LL, Vaknin-Dembinsky A, et al. Interferon-b inhibits toll-like receptor 9 processing in multiple sclerosis. Ann Neurol 2010; 68: 899-906.
74. Paolillo A, Piattella MC, Pantano P, et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 2004; 251: 432-9. (Pubitemid 38501301)
75. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-64. (Pubitemid 34438881)
76. Tintore M, Rovira A, R?o J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67: 968-72. (Pubitemid 44454586)
77. Rudick R, Lee JC, Simon J, et al. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 2006; 60: 236-42. (Pubitemid 44182398)
78. Tomassini V, Paolillo A, Russo P, et al. Predictors of long- term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287-93.
79. Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70: 773-80. (Pubitemid 32554208)
80. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow- up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412-20. (Pubitemid 35285996)
81. Confavreux C, Vukusic S, Adeleine P. Early clinical pre- dictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770-82. (Pubitemid 36372978)
82. Weinshenker BG, Bass B, Rice GP, et al. The natural his- tory of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112: 1419-28. (Pubitemid 20024212)
83. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demye-linating event in multiple sclerosis: CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.
84. Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000; 55: 185-92. (Pubitemid 30604616)
85. Radue EW, Saharaian MA, Pace A, et al. The evaluation of black hole volume evolution as it relates to lesion load, extent of enhancement, and treatment with intramuscular interferon-beta-1a in two relapsing-remitting multiple sclerosis studies. Poster P608 presented at 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2006 Sep 27-30; Madrid.
86. Paty DW, Li DKB; UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7. (Pubitemid 23121952)
87. PRISMS (Prevention of Relapses and Disability by Inter- feron beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
88. Rudick RA, Fisher E, Lee JC, et al. Use of the brain par- enchymal fraction to measure whole brain atrophy in re-lapsing-remitting MS: Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698-704.
89. Zivadinov R, Locatelli L, Cookfair D, et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 2007; 13: 490-501. (Pubitemid 46796509)
90. Barkhof F, Calabresi PA, Miller DH, et al. Imaging out- comes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256-66.
91. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94. (Pubitemid 26100751)
92. Rudick R, Lee JC, Zhang H, et al. Progression of disability at 2 years predicts disability at 8 years: analysis from the phase 3 clinical trial of intramuscular interferon beta-1a. Poster P195 presented at 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2007 Oct 11-14; Prague.
93. IFNb Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
94. CHAMPIONS Study Group. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinat-ing event. Neurology 2006; 66: 678-84.
95. Kinkel RP, Dontchev M, Tanner JP, et al. CHAMPIONS: 10-year follow-up after a clinically isolated syndrome in patients at high risk for developing multiple sclerosis. Mult Scler 2009; 15: S5-277, poster P446.
96. Comi G, Filippi M, Barkhof F, et al. Effect of early inter- feron treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82. (Pubitemid 32488815)
97. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-9. (Pubitemid 44563835)
98. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59: 1496-506. (Pubitemid 35387053)
99. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-60 100.
100. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40: 539-51 (Pubitemid 32738660)